key: cord-0976927-ch6za0ky authors: Diotallevi, Federico; Campanati, Anna; Radi, Giulia; Luchetti, Michele M.; Benfaremo, Devis; Tagliati, Corrado; Simonetti, Oriana; Offidani, Annamaria title: Hydroxychloroquine, dermatology, and SARS‐CoV‐2: Updating an old association date: 2020-07-28 journal: J Med Virol DOI: 10.1002/jmv.26322 sha: f30104ac46cdfc79e5c57b29dc466948a3518fdc doc_id: 976927 cord_uid: ch6za0ky Three months have passed since the World Health Organization (WHO) declared coronavirus disease 19 (COVID-19) as a pandemic on March 11, 2020. Due to the high infection rates and occurrence of severe and fatal cases, the search for effective drugs to treat and control the COVID-19 pandemic has been prioritized by health and political authorities. Antimalarials, well-known for their use in dermatology and rheumatology, are one of the medications with the largest - albeit limited - scientific background warranting their use in the COVID-19 treatment protocols. Hydroxychloroquine (HCQ) has been used for the treatment of COVID-19 in 50 patients in our and other centres in several countries with encouraging results. However, recent studies disprove the real effectiveness of this drug, either alone or when combined with macrolides. As a result, the World Health Organization has discouraged the use of HCQ in the treatment and prevention of COVID-19. Herein we report our experience in the use of hydroxychloroquine for COVID-19 treatment. This article is protected by copyright. All rights reserved. The demand for effective drugs for the treatment and control of the COVID-19 pandemic was given top priority by the health and political authorities, specifically in scenarios with high infection rates and in severe and potentially fatal cases. [3] [4] [5] [6] [7] This is particularly important as the first COVID-19 vaccine is not expected to be ready for clinical trials before the end of this year. 8 Anti-malarial aminoquinoline (chloroquine and hydroxychloroquine) drugs have been used for the treatment of inflammatory diseases for more than 70 years by dermatologists and rheumatologists. 9 Hydroxychloroquine (HCQ) is currently used for the treatment of rheumatoid arthritis, systemic lupus erythematosus, discoid lupus erythematosus (DLE), and photodermatosis, due to its immunomodulatory effect. For example, in the treatment of chronic cutaneous lupus erythematosus, the use of HCQ has a healing rate of more than 85%, proving to be equally effective as 50 mg acitretin but with fewer side effects. 9 Though the mechanisms of action of HCQ are not fully understood, some important aspects are well-known. Chloroquine (CQ), a weak base with a large distribution volume, accumulates at high concentrations in most body tissues, including the lungs. 10 After oral administration, CQ is efficiently absorbed and is present in the blood as a protonated molecule. However, the unprotonated circulating portion easily crosses cell membranes and accumulates in acidic organelles such as lysosomes, Golgi vesicles, and endosomes due to its basic charge. Here, these molecules bind to the free protons, significantly increasing intracellular pH. Thus, many enzymes contained in these organelles that optimally work in an acidic environment, become inhibited. 11 This mechanism is presumably based on the direct antiparasitic, antiviral, and immunomodulatory effects of CQ. Although most of the evidence in this field is regarding CQ, some studies show similar effects when treated with HCQ. Additionally, current data support that the mechanisms of action of these two molecules are similar and that HCQ appears to be significantly less toxic, effectively replacing the use of CQ in the treatment of rheumatic, inflammatory, and autoimmune diseases. 12, 13 Recently hydroxychloroquine has been considered as a potential therapy for COVID-19. 7,13,14 Both CQ and HCQ have been shown to inhibit the SARS-CoV-2 replication in vitro. Additionally, a Chinese clinical trial with more than 100 patients has demonstrated the effective role of chloroquine phosphate (500 mg/day) against COVID-19, inhibiting the exacerbation of pneumonia, improving lung-imaging findings, promoting a virus-negative conversion, and shortening the disease course. 14 However, the N-hydroxyethyl substituted derivative Federico Diotallevi, Giulia Radi, and Anna Campanati equally contributed to this study. of chloroquine, HCQ, is less toxic, more soluble, and has similar or even higher activity towards COVID-19 inhibition. 13, 15 Based on these results, CQ and HCQ are currently recommended for the treatment of hospitalized COVID-19 patients in several countries. 8 Although these medicines have shown promising activity against SARS-CoV-2, they are not free of side effects, specifically causing retinal and cardiovascular toxicity (retinopathy and cardiomyopathy or with conduction system abnormalities), which depend critically on daily dosage and duration of use. 16 Careful considerations should be given before the use of these medications at higher cumulative dosages in patients with known QT prolongation or are at higher risk of arrhythmia. It is recommended that these medicines be used primarily for suspected/confirmed COVID-19 cases and be restricted to hospitalized patients. 17 To date, antimalarials are one of the medications with the largest, albeit limited, scientific background, warranting their use in COVID-19 treatment protocols. Soon, a significant amount of data should be available from clinical trials to verify whether the theoretical strong effects of the drug has a real impact on the survival and recovery of COVID-19 patients. Until then, due to the excellent safety profile and vast experience, their use remains a pillar of current treatment protocols. 13 Particularly in United Hospital of Ancona, Italy, because of the establishment of a task force composed of dermatologists and rheumatologists, 18, 19 HCQ was included in the treatment protocols of patients affected by SARS-CoV2. Briefly, among the 50 patients hospitalized for COVID-19 from March 19th to April 6th, 43 (86%) received HCQ as part of active treatment (Table 1) . Of note, the median duration of treatment was 12 days, and 25 (50%) patients received HCQ together with azithromycin. Three deaths were observed in all elderly patients with SARS-CoV-2 pneumonia and several comorbidities. Other treated patients experienced a slow but progressive improvement, until healing. All patients were taking HCQ, but not azithromycin. In our cohort, there were no emerging arrhythmias that could be related to QT prolongation. Epidemiology of 2019 novel coronavirus disease-19 in Gansu Province, China, 2020. Emerg Infect Dis COVID-19) outbreak situation Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a II level hospital The covid-19 outbreak in Italy: preventive and protective measures adopted by the dermatology unit of bologna university hospital How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic A late-onset widespread skin rash in a previous COVID-19-infected patient: viral or multidrug effect? Management of patients with pemphigus vulgaris during the covid-19 pandemic: experience of a second level dermatology center Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-Ān update on the status Use of antimalarials in dermatology Kinetics of the distribution and elimination of chloroquine in the rat Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19 Current status of potential therapeutic candidates for the COVID-19 crisis Virological and clinical cure in COVID-19 patients treatedwith hydroxychloroquine: a systematic review andmeta-analysis Hydroxychloroquine in systemic lupus erythematosus (SLE) Therapeutic management of COVID-19 patients: a systematic review Skin involvement in SARS-CoV-2 infection: case series Active implications for dermatologists in "SARS-CoV-2 era": personal experience and review of literature Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Global coronavirus pandemic (sars cov-2): past, present, and future of pediatric dermatology Controversial treatments: an updated understanding of the coronavirus disease COMMENTARY hydroxychloroquine in the treatment or prevention of COVID-19 disease, either alone or in association with macrolides, has not be established yet. 22, 23 Recent studies also highlight the misleading nature of anecdotal experiences reported when contrasted with the controlled clinical trials.